Boston Scientific (BSX) Ascends While Market Falls: Some Facts to Note
The latest trading day saw Boston Scientific (BSX) settling at $76.85, representing a +1.45% change from its previous close.
Boston Scientific Corporation (BSX) Is a Trending Stock: Facts to Know Before Betting on It
Boston Scientific (BSX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Alliance Wealth Advisors LLC UT Raises Holdings in Boston Scientific Corporation $BSX
Alliance Wealth Advisors LLC UT increased its position in Boston Scientific Corporation (NYSE: BSX) by 207.7% in the undefined quarter, according to its most recent filing with the SEC. The fund owned 16,560 shares of the medical equipment provider's stock after purchasing an additional 11,178 shares during the period. Alliance Wealth Advisors LLC
BSX vs. ABT: Which MedTech Stock is the Better Investment Now?
Abbott edges out Boston Scientific in the MedTech faceoff, with valuation appeal, strong CGM momentum and strategic deals boosting its investment case.
BSX Posts Q4 Earnings: Should You Buy, Sell or Hold the Stock?
Boston Scientific BSX reported its fourth-quarter 2025 results on Feb. 4. Both top and bottom lines exceeded the company's guidance ranges and topped the respective Zacks Consensus Estimate.
Reassessing The Boston Scientific Bull Thesis
On Wednesday, Boston Scientific (BSX) experienced a loss of nearly one-fifth of its market capitalization in a single trading session. The stock finished at $75.50, reaching a 52-week low, with a volume approximately six times greater than the 3-month average.
The TAVR Pioneer Bets Everything on One Market as Its Competitor Spreads Risk
Edwards Lifesciences (NYSE: EW) and Boston Scientific (NYSE: BSX) both reported strong quarters, but the results reveal fundamentally different strategies in the heart device market.
What Happened To Boston Scientific Stock?
Boston Scientific (BSX), a leading global player in medical devices, announced solid Q4 earnings but offered 2026 guidance that slightly fell short of elevated investor expectations. This response was marked by a drastic, high-volume liquidation event that quickly erased months of gains.
Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Boston Scientific Corporation (BSX) Q4 2025 Earnings Call Transcript
Boston Scientific Corporation (BSX) Q4 2025 Earnings Call Transcript
BSX Stock Dips in Premarket Trading Despite Q4 Earnings, Revenue Beat
BSX beats Q4 EPS and revenue estimates and lifts margins, but shares slide 9.1% in pre-market as investors weigh outlook and guidance.
Boston Scientific (BSX) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Boston Scientific (BSX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
